aTyr Pharma (ATYR) PT Lowered to $1 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ATYR Hot Sheet
Price: $6.18 -6.79%
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on aTyr Pharma (NASDAQ: ATYR) to $1.00 (from $1.50) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Progyny (PGNY) PT Raised to $38 at Citizens After Guidance Raise
- AUTO1 Group SE (AG1:GR) (ATOGF) PT Lowered to EUR26.40 at UBS
- Arbonia AG (ARBN:SW) PT Lowered to CHF5.40 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
